Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

A federal court in Texas has bolstered Novo Nordisk’s efforts to limit the production and sale of compounded versions of its GLP-1 drugs, Wegovy and Ozempic. Here are five notes: ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk shares have dropped ~50% since June ... Despite strong market share and promising early results for Amycretin, competition from Eli Lilly and regulatory risks pose significant challenges.

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Novo Nordisk's sales have been growing fast thanks ... Last year, the Danish company delivered promising early-stage results for amycretin, another GLP-1 option. Amycretin is a dual agonist ...